Sumitomo Pharma stock
Price history
−17.92% over the period1 year: from ¥2,458.50 (November 17, 2025) to ¥2,018.00 (November 16, 2026), −17.92%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | ¥2,018.00 |
| October 30, 2026 | ¥1,884.50 |
| September 30, 2026 | ¥1,626.50 |
| August 31, 2026 | ¥1,554.00 |
| July 31, 2026 | ¥1,248.00 |
| June 30, 2026 | ¥1,501.00 |
| May 29, 2026 | ¥1,623.00 |
| April 30, 2026 | ¥1,719.50 |
| March 31, 2026 | ¥2,075.50 |
| February 27, 2026 | ¥2,524.00 |
| January 30, 2026 | ¥2,297.00 |
| December 30, 2025 | ¥2,318.00 |
| November 28, 2025 | ¥2,730.00 |
| November 17, 2025 | ¥2,458.50 |
At a glance
The company
Manufactures and sells pharmaceutical products for treating Parkinson's disease, type 2 diabetes, uterine fibroids, overactive bladder, and other conditions in Japan, North America and Asia
Latest results
Quarter to September 30, 2026 · EPS ¥47.46 (estimate ¥23.90)
Next event
TickerLandia's take on Sumitomo Pharma
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 7.5 vs a median of 13 over its last 8 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 19 vs 28 (−32%) in a group of 11.
- Strong point: Market momentum (74/100 in its group). Weak point: Earnings stability (11/100).
- “Below historical valuation” (Japan): No. 9 of 20.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−38.63% from the 52-week high
Analysts · 7 analysts
Average target¥2,242.86+11.14% vs. price
Buy 5 · Hold 2 · Sell 0 · Buy
TickerLandia Fingerprint: Sumitomo Pharma
Compared with similar companies: very low earnings stability.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.
Priceaverage57
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 118.4 99 Price/book 2.11 37 P/E (trailing 12 months) 19.2 36 EV/EBITDA 58.3 96 Price/sales 1.85 20 Profitabilitylow23
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 53.3% 24 ROE 13.3% 47 ROA −0.1% 9 Net margin 9.4% 29 Operating margin −0.4% 6 Earnings stabilityvery low11
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 52.8% 4 Loss-making yearscounts in reverse: lower means more earnings stability 2 of 5 annual reports 18 Growthlow22
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +15.00% 59 Average revenue growth (3 years) −6.56% 1 Earnings growth (year over year) −78.50% 4 Financial strengthlow37
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 1.97 28 Current ratio 1.36 29 Interest coverage 9.84 37 Debt/equitycounts in reverse: lower means more financial strength 0.32 54 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumstrong74
How the stock has moved compared with the market.
Metric Value Position in group Distance from 200-day average +15.06% 86 Relative strength (3 months) +67.17% 100 Relative strength (6 months) +27.87% 86 1-year return −14.14% 25 Riskhigh68
How much the price swings.
Metric Value Position in group Volatility (60 days) 57.4% 78 Beta (1 year) 0.55 37 Maximum drawdown (12 months) 61.4% 90
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Sumitomo Pharma is cheaper than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2026), Sumitomo Pharma's P/E today is 7.50, below the median of its last 8 fiscal years (13.4; between 7.72 and 25.2 from 2017 to 2026). Sumitomo Pharma's P/E (trailing 12 months): 19.2, −32% against the median of a group of 11 similar companies (28.4).
Compared with 11 similar companies
| Metric | Sumitomo Pharma | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 19.2 | Middle | |
| Forward P/E | 118.4 | High | |
| Operating margin | -0.4% | Low | |
| ROE | 13.3% | Middle | |
| Debt/equity | 0.32 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Sumitomo Pharma. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
¥137B
Latest quarter · Q3 2026
Net income
¥21.24B
Latest quarter · Q3 2026
Quarterly net margin
15.5%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- ¥909.75B
- P/E
- 19.2
- EPS
- ¥105.38
- Volume
- 3.07M
- Daily trading
- €50.57M
How Sumitomo Pharma is changing
All resultsRevenue fell 2.6% a year on average over the last 5 years
Operating margin rose from −22.7% to 11.6%
Profitable in 3 of 5 fiscal years
Returns
Sumitomo Pharma returns with dividends
¥1,000 invested in Sumitomo Pharma 5 years ago, on November 16, 2021, would be worth ¥1,364 today with dividends reinvested: +36.37% in total, +6.40% per year. On price alone it would be ¥1,319 (+31.90%).
| Period | Sumitomo Pharma | Nikkei 225 | ¥1,000 becomes |
|---|---|---|---|
| 1 month | +9.64% | −6.39% | ¥1,096 |
| 6 months | +18.08% | −0.42% | ¥1,181 |
| Year to date | −12.94% | +21.48% | ¥871 |
| 1 year | −17.92% | +21.52% | ¥821 |
| 3 years | +342.54% | +82.95% | ¥4,425 |
| 5 years | +36.37% | +105.15% | ¥1,364 |
| 10 years | +21.24% | +242.35% | ¥1,212 |
Over the last 6 months it has done better than 57% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. Nikkei 225: price only. Calculate your investment
The chart in detail
Sumitomo Pharma: technical analysis
Sumitomo Pharma shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 49.9% below its all-time closing high (¥4,030.00, December 5, 2018).
- Trend
- No clear trend
- RSI (14 sessions)
- 61
- Between 30 and 70
- vs 200-session average
- +14.57%
Support and resistance
Price areas where Sumitomo Pharma has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance¥2,270.00+12.49%2 touches, last on April 2, 2026
- Resistance¥2,213.00+9.66%2 touches, last on April 17, 2026
- Resistance¥2,152.00+6.64%2 touches, last on November 5, 2026
- Last price¥2,018.00
- Support¥1,794.60−11.07%5 touches, last on November 6, 2026
- Support¥1,561.17−22.64%3 touches, last on October 9, 2026
- Support¥1,483.50−26.49%2 touches, last on September 16, 2026
Volatility and risk
Over the last year it has moved less than the Nikkei 225.
- Beta (1 year) vs Nikkei 225
- 0.56
- Volatility (60 sessions, annualised)
- 57.4%
- Largest fall in the last year
- −61.37%
Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Sumitomo Pharma: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Sumitomo Pharma has been November: +3.47% on average, positive in 21 years out of 36. The weakest has been May: −1.98% on average, positive in 16 years out of 37.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.99% | +0.22% | 19 of 36 |
| February | +1.87% | +1.72% | 22 of 37 |
| March | +0.13% | −1.49% | 13 of 37 |
| April | −0.46% | −0.54% | 17 of 37 |
| May | −1.98% | −1.03% | 16 of 37 |
| June | +1.81% | +0.31% | 19 of 37 |
| July | +0.48% | +1.05% | 20 of 37 |
| August | +1.38% | −0.36% | 15 of 37 |
| September | +0.57% | +0.29% | 19 of 37 |
| October | −1.22% | −2.24% | 15 of 37 |
| November | +3.47% | +1.88% | 21 of 36 |
| December | −1.13% | −0.62% | 16 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Sumitomo Pharma and its competitors
Pharmaceutical manufacturing and sales form the core of Sumitomo Pharma's operations, covering prescription medicines for neurological and metabolic conditions, women's health and overactive bladder. Its range also includes atypical antipsychotics, generic drugs, antiepileptic medicines, carbapenem antibiotics and treatments for pediatric congenital athymia. The group sells veterinary medicines and medical devices in Japan, North America and Asia, and it works with Otsuka Pharmaceutical under a collaboration and license agreement.
- Headquarters
- Osaka, Japan
- Employees
- 4,980
- Founded
- 1897
- Chief executive
- Toru Kimura
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Sumitomo Pharma4506 | $5.69B | -0.4% | 19.2 | +18.08% |
| Kyowa Kirin4151 | $8.46B | 21.8% | 16.6 | +9.73% |
| Eisai4523 | $9.14B | 6.7% | 33.3 | +11.79% |
| CiplaCIPLA | $11.93B | 13.0% | 38.8 | −2.63% |
| Zhejiang NHU002001 | $12.3B | 33.8% | 10.9 | −21.99% |
| Zydus LifesciencesZYDUSLIFE | $12.59B | 17.2% | 28.4 | +17.82% |
Same industry or related industries, similar size. Compare Sumitomo Pharma with its competitors · Full profile
